Abstract

The treatment of fulminating staphylococcal infection is still a great problem in spite of the rapid development of chemotherapy. This is mainly due to three factors: [1] the ability of staphylococci to become chemoresistant during treatment, [2] the rapid course of staphylococcal infection that makes patients extremely ill before a diagnosis can be established and, therefore, having only a short time left for chemotherapy, and [3] extensive focal lesions with pus and necrotic tissue that delays and restricts the activity of the antibiotics and favors the development of bacterial resistance.

The good results obtained with the new semisynthetic penicillins unaffected